Within recent news,
Bristol-Myers Squibb (BMY) has been experiencing a plethora of actions. Despite the
stock sinking and underperforming when compared to competitors, institutions such as
RFG Advisory LLC and
Douglas Lane & Associates LLC are raising their stakes in BMY. Coupled with that, the company elected
Michael R. McMullen to their Board of Directors, announced dividends, and launched a $1.5 billion cost cut as it posts quarterly loss. Bristol Myers exhibits deep commitment to
innovation and advancement in medical sciences, with aims to launch 16 new products by 2030, and receive FDA approval for several others. The company has however faced challenges, including a sluggish sale of some newer drugs and failed therapies in their late-stage study. In a bid for expansion, Bristol Myers Squibb has made multibillion-dollar acquisitions such as
RayzeBio and
Karuna Therapeutics to boost its neuroscience portfolio.
Bristol-Myers Squibb News Analytics from Wed, 20 Dec 2023 08:00:00 GMT to Sun, 23 Jun 2024 15:49:19 GMT -
Rating -2
- Innovation 4
- Information 8
- Rumor -3
